Michael Higgins
Stock Analyst at Ladenburg Thalmann
(1.81)
# 3,061
Out of 4,847 analysts
21
Total ratings
29.41%
Success rate
5.55%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $14.45 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $69 | $9.55 | +619.90% | 3 | Apr 8, 2024 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $0.30 | +2,243.49% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $0.88 | +1,597.22% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $60 | $1.07 | +5,507.48% | 2 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $65.67 | -46.70% | 3 | Mar 2, 2023 | |
| PHGE BiomX | Maintains: Buy | $130 → $80 | $0.50 | +15,868.06% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | $105 | $7.26 | +1,346.28% | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | $29 | $40.27 | -27.99% | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $2.40 | - | 1 | Sep 27, 2017 | |
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.45
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $9.55
Upside: +619.90%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $0.30
Upside: +2,243.49%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $0.88
Upside: +1,597.22%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $60
Current: $1.07
Upside: +5,507.48%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $65.67
Upside: -46.70%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.50
Upside: +15,868.06%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $7.26
Upside: +1,346.28%
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $40.27
Upside: -27.99%
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $2.40
Upside: -